Utilization of a 3D Printed Mechanical Balancer During Total Knee Arthroplasty (TKA)
Launched by NYU LANGONE HEALTH · Oct 22, 2024
Trial Information
Current as of November 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new device called a 3D-printed mechanical balancer, which will be used during knee replacement surgery (known as total knee arthroplasty, or TKA). The purpose of the trial is to see how well this device works in helping surgeons make the knee joint balanced during the operation. The study will include 50 patients who are scheduled to have their first knee replacement surgery. It’s important to note that while the device will be used during surgery, it won't influence the surgeons' decisions about how to perform the procedure.
To be eligible for this trial, participants should be planning to have a primary total knee arthroplasty and must be able to provide written consent for the study. The trial is not yet recruiting participants, and it welcomes all individuals aged 65 to 74, regardless of gender. If you decide to participate, you will receive the standard care for knee replacement surgery along with the use of this new device during your operation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Surgical candidates undergoing primary TKA
- Exclusion Criteria:
- • Patient is unable to provide written consent
About Nyu Langone Health
NYU Langone Health is a premier academic medical center located in New York City, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a leading sponsor of clinical trials, NYU Langone Health integrates cutting-edge scientific inquiry with patient-centered care, striving to develop new therapies and improve health outcomes across a wide range of medical conditions. The institution is dedicated to fostering collaboration among researchers, clinicians, and patients, ensuring rigorous adherence to ethical standards and regulatory guidelines in all clinical research initiatives. By leveraging its extensive resources and expertise, NYU Langone Health aims to contribute significantly to the advancement of medical knowledge and the enhancement of patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Peter Walker
Principal Investigator
NYU Langone Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported